// App-Quantinova.ai

3129 : Predictive biomarker identification for response to vantictumab (OMP-18R5; anti-Frizzled) using primary patient-derived human pancreatic tumor xenografts

Researchers

Presenter

  • CHUN ZHANG

Principal Investigators

  • Fiore Cattaruzza

  • Pete Yeung

  • Wan-Ching Yen

  • Marcus Fischer

  • Claire Guo

  • Alayne Brunner

  • Min Wang

  • Belinda Cancilla

  • Austin Gurney

  • Rainer Brachmann

  • John Lewicki

  • Tim Hoey

  • Ann M. Kapoun

Medical Centers

  • OncoMed Pharmaceuticals Inc., Redwood City, CA

Locations

  • United States

Companies

  • OncoMed Pharmaceutic

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreatic cancer

  • Solid malignancies

Biomarkers

  • Acetyl-CoA carboxylase

  • Insulin Like Growth Factor 2

  • Transforming growth factor beta 3

Drug/Treatment

  • Gemcitabine

  • Vantictumab

  • Paclitaxel

  • OMP18R5

Outcome

  • N/A

Study Design

  • Pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved